Efficacy and Safety from the ASCENT Study

2021 Year in Review - Triple-Negative Breast Cancer —December 14, 2021

Categories:

Breast Cancer

Sacituzumab govitecan-hziy (SG) is a first-in-class antibody and topoisomerase inhibitor conjugate targeting Trop-2, a compelling target in patients with metastatic triple-negative breast cancer (mTNBC). SG is indicated in unresectable locally advanced or mTNBC patients who have received ≥2 prior systemic therapies, ≥1 being for metastatic disease.1 SG showed positive efficacy results from the phase 3 ASCENT study and demonstrated a statistically significant and clinically meaningful 59% reduction in the risk of disease worsening or death (hazard ratio, 0.41; 95% confidence interval, 0.32-0.52; P <.001).2 The key takeaways from the study were that patients in the SG group lived longer with less disease progression and had more tumors that reduced in size or disappeared.3

ASCENT was a phase 3 trial with mTNBC patients designed to validate the efficacy and safety of SG observed in an earlier phase 2 study of heavily pretreated patients with mTNBC.4 Results from ASCENT warranted early trial cessation and were the basis for the FDA’s accelerated approval of SG for mTNBC, a disease with few other treatment options.4 The primary end point for the study was progression-free survival. The ASCENT study began in November 2017 and ended in March 2020. A total of 529 patients with mTNBC enrolled, and patients were randomized into an SG arm or an arm that received chemotherapy chosen by the physician (either eribulin, vinorelbine, capecitabine, or gemcitabine).3

Patients in the SG group experienced more side effects than patients in the chemotherapy group.3 Safety was assessed in any patient who received ≥1 doses of medication, SG or chemo.3 This resulted in a safety analysis of 258 patients receiving SG and 224 patients receiving chemo. The most common side effects of SG were neutropenia, diarrhea, nausea, alopecia, fatigue, and anemia.3 Neutropenia was managed by reducing or delaying treatment; oral antidiarrhea medication, such as loperamide, was used to manage patients who developed diarrhea; and nausea was managed by prompt symptomatic intervention through growth factor support and medication to treat nausea and vomiting.3 There were no treatment-related deaths in the SG group.3

ASCENT results were so compelling, the decision was made to halt the study early.4 The fast-track FDA approval enabled SG to be included in the National Comprehensive Cancer Network Breast Cancer Guidelines soon after approval.5 FDA approval of SG for mTNBC and its addition into the National Comprehensive Cancer Network Breast Cancer Guidelines has provided breast cancer patients and breast cancer oncology teams with another tool to use against a devastating disease.

References

  1. Trodelvy (sacituzumab govitecan-hziy) [package insert]. Foster City, CA: Gilead Sciences, Inc; April 2021.
  2. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529-1541.
  3. Bardia A, Hurvitz SA, Rugo HS, et al. A plain language summary of the ASCENT study: sacituzumab govitecan for metastatic triple-negative breast cancer. Future Oncol. 2021;17:3911-3924.
  4. Cancer Network. Phase III ASCENT study of metastatic TNBC halted due to compelling efficacy. Updated April 2020. www.cancernetwork.com/view/phase-iii-ascent-study-metastatic-tnbc-halted-due-compelling-efficacy. Accessed December 1, 2021.
  5. Gilead. Gilead statement on new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) recommendation for sacituzumab govitecan-hziy (Trodelvy) in second-line and later metastatic triple-negative breast cancer. Updated September 2021. www.gilead.com/news-and-press/company-statements/gilead-statement-on-new-nccn-clinical-practice-guidelines-in-oncology-nccn-guidelines-recommendation-for-sacituzumab-govitecan-hziy-trodelvy-in-second-line-and-later-metastatic-triple-negative-breast-cancer. Accessed December 1, 2021.
Related Articles
Key Breast Cancer Abstracts in 2023 and Innovations in Ovarian Function Suppression:
Matteo Lambertini, MD, PhD, Erica Stringer-Reasor, MD, Director, Sara M. Tolaney, MD, MPH
|
Video Library
Please join Sara Tolaney, MD, MPH, Dana-Farber Cancer Center, Boston, MA; Erica Stringer-Reasor, MD, University of Alabama, Birmingham; and Matteo Lambertini, MD, PhD, University of Genoa, Italy, as they provide expert commentary on key breast cancer abstracts presented at the 2023 ASCO Annual Meetings that will impact young women with ER+/HER2- breast cancer.
Navigating Oral Therapy in Breast Cancer: Practice Strategies to Promote Medication Adherence
Video Library
The Academy of Oncology Nurse & Patient Navigators (AONN+) and Eli Lilly and Company Medical Affairs are pleased to present a live webinar designed to facilitate conversations with patients regarding adherence to breast cancer treatments. Attendees will have an opportunity to participate in a live Q&A following the presentation.
Improving Adherence to Oral Oncolytics in Breast Cancer: The Pivotal Role of Nurse Navigators
September 2022 Vol 13, No 9
Oral oncolytic drugs have a multitude of benefits for patients, including ease of use, improved quality of life, fewer clinic visits, and no need for IV therapy.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country